Journal of Clinical Oncology, Vol 1, 164-169, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors

M Zelen

Guidelines are proposed for the reporting of clinical trials. These are meant to be used for both authors and journal editors. Specific proposals are made for: reporting the population under study, actual therapy used, describing the study design, accounting of patients, follow-up statistics, and describing the quality control of the data. Nonrandomized studies require special discussion. Such studies potentially have substantial biases which can lead to incorrect conclusions. Six areas of biases arising in nonrandomized studies are pointed out which should require a discussion in an acceptable published paper. The presentation of statistical results and the reporting of early studies present unusually difficult problems. Guidelines are presented for statistical analyses which, although simple to implement in practice, are not generally used. A proposal is made for the publication of early results of a study which require that the authors agree to follow and periodically report on their trial to the journal editor. If the early conclusions change with additional follow-up, the editor should notify its readers. The adoption of these guidelines can be an important force in raising the scientific level of the reporting of clinical trials.

This article has been cited by other articles:

				S. Mathoulin-Pelissier, S. Gourgou-Bourgade, F. Bonnetain, and A. Kramar Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals J. Clin. Oncol., August 1, 2008; 26(22): 3721 - 3726. [Abstract] [Full Text] [PDF]

				T. Lang Documenting research in scientific articles: guidelines for authors: reporting research designs and activities. Chest, October 1, 2006; 130(4): 1263 - 1268. [Full Text] [PDF]

				S. P. Treon, M. A. Gertz, M. Dimopoulos, A. Anagnostopoulos, J. Blade, A. R. Branagan, R. Garcia-Sanz, S. Johnson, E. Kimby, V. LeBlond, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia Blood, May 1, 2006; 107(9): 3442 - 3446. [Abstract] [Full Text] [PDF]

				B. Freidlin, O. S. Breathnach, and B. E. Johnson A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2003; 9(3): 917 - 922. [Abstract] [Full Text] [PDF]

				T. J. Miner, D. P. Jaques, and C. D. Shriver A Prospective Evaluation of Patients Undergoing Surgery for the Palliation of an Advanced Malignancy Ann. Surg. Oncol., August 1, 2002; 9(7): 696 - 703. [Abstract] [Full Text] [PDF]

				M. J. Dooley and J. Vernon Reproducibility of treatment methodologies detailed in contemporary clinical trial reports Journal of Oncology Pharmacy Practice, June 1, 2000; 6(2): 50 - 54. [Abstract] [PDF]

				D. Moher CONSORT: An Evolving Tool to Help Improve the Quality of Reports of Randomized Controlled Trials JAMA, May 13, 1998; 279(18): 1489 - 1491. [Full Text] [PDF]

				J. A. Hokanson, C. M. Stiernberg, M. S. McCracken, and F. B. Quinn Jr The Reporting of Statistical Techniques in Otolaryngology Journals Arch Otolaryngol Head Neck Surg, January 1, 1987; 113(1): 45 - 50. [Abstract] [PDF]